Anti-Smoking Legislation Vital for Nicotine Addiction to go up in Smoke, Say GBI Research Specialists

10 Sep 2012 • by Natalie Aster

Anti-smoking legislation and structured support from healthcare providers is essential to achieve widespread smoking cessation, claims a new report by healthcare experts GBI Research.

The new report "Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities" by GBI Research argues that the effectiveness of current pharmaceutical treatments depends as much on enforced legislation, such as smoking bans, and support from healthcare providers as an individual’s willingness to quit.

According to the World Health Organization (WHO), up to half of all ‘lifelong’ tobacco users will die from a tobacco-related disease, while the five million deaths that occur as a result of smoking every year outnumber the collective lives lost to HIV/AIDS, malaria and tuberculosis. Nicotine addiction therefore represents a serious public health risk and must be met with effective cessation therapies.

GBI Research claims that the prevalent population for nicotine addiction stood at 136.7 million in 2011, while the ‘diagnosed’ population, defined as those going to visit a physician concerning smoking cessation, was only 40 million. Furthermore, GlaxoSmithKline claims that while 70% of smokers want to quit less than 5% actually do, indicating a massive opportunity for companies willing to enter the market.

Popular Nicotine Replacement Therapies (NRTs) are conveniently available over-the-counter and account for 75% of all smoking cessation therapies sold worldwide, with patches, gum, lozenges, sprays and inhalers available to deliver doses of nicotine and reduce the effects of withdrawal.

The increasing emergence of smokeless electronic ‘e-cigarette’ products have split opinion as effective treatments as, while e-cigarettes are often marketed as anti-smoking treatments, they are often sponsored by large tobacco companies and arguably serve to keep smokers addicted. Furthermore, the ‘e-cigarette’ market is currently unregulated, while low-grade nicotine is often used, which may have unpleasant and possibly dangerous side-effects.

Report Details:

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities
Published: August, 2012
Pages: 97
Price: US$ 3.500,00

More information can be found in the report “Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities” by GBI Research.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com